Recursion(US:RXRX) ZACKSยท2025-10-16 22:51Company Performance - Recursion Pharmaceuticals (RXRX) ended the recent trading session at $6.36, showing a -6.33% change from the previous day's closing price, which lagged behind the S&P 500's daily loss of 0.63% [1] - Over the past month, shares of Recursion Pharmaceuticals have appreciated by 44.16%, outperforming the Medical sector's gain of 3.09% and the S&P 500's gain of 0.92% [1] Upcoming Earnings - Analysts expect Recursion Pharmaceuticals to post earnings of -$0.35 per share in the upcoming earnings release, marking a year-over-year decline of 2.94% [2] - The current consensus estimate forecasts revenue to be $17.45 million, indicating a 33.11% decline compared to the same quarter of the previous year [2] Fiscal Year Projections - For the entire fiscal year, Zacks Consensus Estimates project earnings of -$1.5 per share and revenue of $72.38 million, representing changes of +11.24% and +23.02%, respectively, from the prior year [3] - Recent changes to analyst estimates for Recursion Pharmaceuticals reflect shifting dynamics in short-term business patterns, with positive estimate revisions indicating optimism about the business outlook [3] Zacks Rank and Industry Performance - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), has a track record of exceeding expectations, with stocks rated 1 delivering an average annual return of +25% since 1988 [5] - Currently, Recursion Pharmaceuticals holds a Zacks Rank of 4 (Sell), with a 1.92% fall in the Zacks Consensus EPS estimate over the past month [5] - The Medical - Biomedical and Genetics industry, part of the Medical sector, has a Zacks Industry Rank of 84, placing it in the top 35% of all 250+ industries [6]